文献速递主动脉疾病

症状性穿通性主动脉溃疡和壁内血肿的TEVAR治疗与不良结局相关

Thoracic endovascular aortic repair for symptomatic penetrating aortic ulcers and intramural hematomas is associated with poor outcomes.
PubMed 文献 · J Vasc Surg · 2020-12-16

基于血管质量倡议(VQI)数据库2011-2020年1042例因穿通性主动脉溃疡(PAU)和/或壁内血肿(IMH)行胸主动脉腔内修复(TEVAR)的患者,症状性患者较无症状患者主要不良事件、院内再干预和死亡率更高,无症状患者无治疗相关死亡,总体预后取决于合并症。

要点

  • 症状性PAU/IMH行TEVAR的主要不良事件发生率为20.6%,显著高于无症状者的6.9%。
  • 无症状患者随访期间无治疗相关死亡,预后主要取决于基础合并症。
  • 需开展自然病史研究并制定PAU/IMH择期修复的明确指南。

核心结论

  • 症状性PAU/IMH患者行TEVAR的围手术期和随访期死亡率和发病率显著高于无症状患者。
  • 无症状患者行TEVAR随访期间无治疗相关死亡,总体预后主要取决于合并症。

研究设计与样本

  • 回顾性队列研究,使用血管质量倡议(VQI)数据库2011年1月至2020年2月的数据。
  • 纳入1042例年龄≥18岁因PAU和/或IMH行TEVAR的患者,其中809例有随访数据。

主要发现

  • 队列平均年龄71.1岁,54.8%为女性,74%有症状,44.5%为非择期修复。
  • 主要不良事件(MAE)发生率为17%,院内死亡率为4.3%,其中73%为治疗相关。
  • 随访809例(平均25.1±19个月),全因死亡率为10.6%。
  • 症状性患者MAE发生率20.6% vs 无症状者6.9%(P < .001),院内再干预率5.9% vs 1.5%(P = .002),院内死亡率5.6% vs 0.7%(log-rank P = .015),住院时间6.9 vs 3.7天(P < .0001)。
  • 随访期症状性患者晚期死亡率12.2% vs 6.5%(log-rank P = .025),所有治疗相关死亡均限于症状性组。

关键数值与推荐

  • MAE独立预测因素:冠心病史、非白种人、急诊手术指征、破裂表现、使用≥2个内移植物。
  • 晚期死亡预测因素:年龄>70岁、破裂表现、慢性阻塞性肺疾病史和终末期肾病。

临床怎么用

  • 对症状性PAU/IMH患者行TEVAR应认识到较高的围手术期和晚期不良事件风险。
  • 无症状患者择期TEVAR的预后主要取决于合并症,治疗相关死亡风险低。
  • 需进一步自然病史研究以确定PAU/IMH择期修复的阈值和指南。

局限性

  • 回顾性数据库研究,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The natural history of penetrating aortic ulcers (PAUs) and intramural hematomas (IMHs) of the aorta has not been well described. Although repair is warranted for rupture, unremitting chest pain, or growth, no threshold has been established for treating those found incidentally. Thoracic endovascular aortic repair (TEVAR) offers an attractive approach for treating these pathologic entities. However, the periprocedural and postoperative outcomes have not been well defined. METHODS: Patients aged ≥18 years identified in the Vascular Quality Initiative database who had undergone TEVAR for PAUs and/or IMHs from January 2011 to February 2020 were included. We identified 1042 patients, of whom 809 had follow-up data available. The patient demographics and comorbidities were analyzed to identify the risk factors for major adverse events (MAEs) and postoperative and late mortality. RESULTS: The cohort was 54.8% female, and 69.9% were former smokers, with a mean age of 71.1 years. Comorbidities were prevalent, with 57.8% classified as having American Society of Anesthesiologists class 4. Of the 1042 patients, 89.8% had hypertension, 28.3% chronic obstructive pulmonary disease, 17.9% coronary artery disease, and 12.2% congestive heart failure. Patients were predominately symptomatic (74%), and 44.5% had undergone nonelective repair. The MAE incidence was 17%. The independent predictors of MAEs were a history of coronary artery disease, nonwhite race, emergent procedural indication, ruptured presentation, and deployment of two or more endografts. In-hospital mortality was 4.3%. Of the index hospitalization mortalities, 73% were treatment related. For the 809 patients with follow-up (mean, 25.1 ± 19 months), the all-cause mortality was 10.6%. The predictors of late mortality during follow-up included age >70 years, ruptured presentation, and a history of chronic obstructive pulmonary disease and end-stage renal disease. A subset analysis comparing symptomatic (74%) vs asymptomatic (26%) patients demonstrated that the former were frequently women (58.2% vs 45.3%; P < .001), with a greater incidence of MAEs (20.6% vs 6.9%; P < .001), including higher in-hospital reintervention rates (5.9% vs 1.5%; P = .002) and mortality (5.6% vs 0.7%; log-rank P = .015), and a prolonged length of stay (6.9 vs 3.7 days; P < .0001), despite similar procedural risks. During follow-up, late mortality was greater in the symptomatic cohort (12.2% vs 6.5%; log-rank P = .025), with all treatment-related mortalities limited to the symptomatic group. CONCLUSIONS: We found significantly greater morbidity and mortality in symptomatic patients undergoing repair compared with asymptomatic patients, despite similar baseline characteristics. Asymptomatic patients treated with TEVAR had no treatment-related mortality during follow-up, with the overall prognosis largely dependent on preexisting comorbidities. These findings, in conjunction with increasing evidence highlighting the risk of disease progression and attendant morbidity associated with these aortic entities, suggest a need for natural history studies and definitive guidelines on the elective repair of IMHs and PAUs.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Rokosh RS, Rockman CB, Patel VI, et al. Thoracic endovascular aortic repair for symptomatic penetrating aortic ulcers and intramural hematomas is associated with poor outcomes. J Vasc Surg. 2020. PMID: 33340703. doi:10.1016/j.jvs.2020.11.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。